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Abstract 
 
Novel bilayer mucoadhesive patches for delivery of clobetasol-17-propionate to the oral 
mucosa to treat oral lichen planus; an in vitro and in vivo evaluation 
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Objectives: 
Oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS) are chronic inflammatory 
conditions often characterised by erosive and/or painful oral lesions that have a 
considerable impact on quality of life. Current treatment often necessitates the use of 
steroids in the form of mouthwashes, creams or ointments but these are often ineffective 
due to inadequate drug contact times with the lesion.  Here we evaluate the performance of 
novel bilayer mucoadhesive patches for uni-directional delivery of the steroid Clobetasol-
17-propionate to the oral mucosa. 
 
Methods: 
Electrospun polymeric patches with an impermeable backing layer and mucoadhesive drug 
delivery layer were produced and characterised for their physical properties in the 
laboratory. The drug release profile, drug penetration and cytotoxicity of the system in 
delivering Clobetasol-17-proprionate was evaluated using ex-vivo porcine oral mucosa and 
tissue engineered human oral mucosa. The ability of the system to deliver Clobetasol -17-
proprionate effectively into the oral mucosa, and local and systemic drug safety was then 
confirmed in in vivo mini-pig studies before evaluation of residence time and acceptability 
of the drug delivery system in a human volunteer study. 
 
Results: 
Clobetasol-17-propionate incorporated into the patches was released in a sustained manner 
in both tissue-engineered oral mucosa and ex vivo porcine mucosa. Clobetasol-17 
propionate-loaded patches were further evaluated for residence time and drug release in an 
in vivo animal model and demonstrated prolonged adhesion and drug release at 
therapeutic-relevant doses and time points without local or systemic toxicity. Human 
studies confirmed long adhesion (residence) times and high levels of patient acceptability 
for use of the oral adhesive patches for treatment of oral mucosal disease.  
 
Conclusions: 
These data show that electrospun patches are adherent to mucosal tissue without causing 
tissue damage, and can successfully be loaded with and release Clobetasol and potentially 
other clinically active drugs into the oral mucosae in a sustained therapeutic manner. These 
patches hold great promise for improving the treatment of OLP, RAS and other 
immunoinflammatory oral diseases and are ready to enter phase 2 clinical trials. 
